Abstract 431P
Background
Glioma is one of the most common types of tumor of the central nervous system with high morbidity and mortality. Based on this fact that the prognosis of patients with high- grade glioma is poor, it is very important to develop new diagnostic and therapeutic strategies covering more efficient methods and drugs. Recent studies have demonstrated that Long non-coding RNAs (lncRNAs) may act as potential inducers or suppressors of numerous types of tumors including glioma. Besides, there are more expression of lncRNAs than coding mRNAs and miRNAs in specific tissues.In this study we evaluated two lncRNAs including MEG3 and MDC1-AS1 which seemed to be involved in the initiation and progression of high grade Gliomas.
Methods
The expression of lncRNAs were studied on 150 paraffin tissue block samples of Iranian participants, including 37 samples of low-grade gliomas(I&II), 58 samples of high grade glioma (III& IV) and 95 samples of non-tumoral tissues. After RNA extraction and complementary DNA synthesis(cDNA), probe-based (Taqman) Real-time PCR were used to evaluate lncRNAs expression level followed by statistical analizing.
Results
Our analysis, indicates that lncRNAs including MEG3 and MDC-AS1 are down-regulated (p =0.001) in high grade glioma tumors (grade III & IV) in comparison to low grade gliomas (grade I and II) and non-tumoral tissues.
Conclusions
The results show that there are critical expression differences i n MEG3 and MDC1-AS1 lncRNAs as tumor suppressor genes between high and low-grade gliomas. Comprising with other reports, it could be assumed that expression of MEG3 and MDC1-AS1 lncRNAs may serve as potential biomarkers and also therapeutic targets for detection and treatment of glioma tumors. Key words: Quantitative, lncRNAs, glioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Arash Moradi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session